Brazil's health regulatory agency, Anvisa, has received the application for approval of the CHIKV VLP chikungunya vaccine manufactured by the Danish pharmaceutical company Bavarian Nordic. This strategic step was taken in partnership with local pharmaceutical company Eurofarma, which was appointed to handle the regulatory, commercialization, and distribution aspects of the vaccine in Brazil.
This single-dose vaccine is specifically designed as a non-infectious immunization capable of rapidly inducing immunity. Local authorities are considering the vaccine for use in individuals aged 12 and older, as a preventive measure to curb the spread of the chikungunya virus, which often causes severe joint pain and chronic arthritis in sufferers.
Previously, the vaccine has received approval from various international regulatory bodies, including those in the United States, Europe, the United Kingdom, Switzerland, and Canada. With the high prevalence of chikungunya infections in Brazil, the introduction of this vaccine is expected to become a crucial instrument in strengthening public health infrastructure and mitigating the long-term impact of the disease in Brazil.
